Depression associated with antiretroviral drug therapy in HIV: Case report and overview

International Journal of STD and AIDS

Volumn 23, Issue 6, 2012, Pages

  Kaestner, F ^a   Anneken, K ^a   Mostert, C ^a   Reichelt, D ^a   Rothermundt, M ^a   Evers, S ^a   Husstedt, I W ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Adherence; Adverse effects; Affective disorders; Antiretroviral therapy; Depression; HIV AIDS

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMITRIPTYLINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; LAMIVUDINE; LAMOTRIGINE; MIRTAZAPINE; NELFINAVIR; PERAZINE; RITONAVIR; VENLAFAXINE; ZIDOVUDINE;

ADULT; ANHEDONIA; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; BIPOLAR DISORDER; CASE REPORT; DISEASE ASSOCIATION; DISEASE COURSE; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; FAMILY HISTORY; FATIGUE; HIV ASSOCIATED COLITIS; HIV ASSOCIATED THROMBOCYTOPENIA; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR DEPRESSION; MALE; NEUROPSYCHOLOGICAL TEST; PLEURA EMPYEMA; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; SLEEP DISORDER; SUICIDAL IDEATION; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; BIPOLAR DISORDER; DEPRESSION; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE;

EID: 84864042418     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2009.009451     Document Type: Article

References (59)

1. Arendt G. Affective disorders in patients with HIV infection. CNS Drugs 2006;20:507-518
2. Cruess DG, Evans DL, Repetto MJ, Gettes D, Douglas DD, Petitto JM. Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease. Biol Psychiatry 2003;54:307-316
3. Husstedt IW, Frohne L, Bockenholt SC, et al. Impact of highly activated antiretroviral therapy on cognitive processing in HIV infection: cross-sectional and longitudinal studies of event-related potential. AIDS Res Hum Retrovirus 2000;18:485-490
4. Judd FK, Cockram AM, Komiti A, Mijch AM, Hoy J, Bell R. Depressive symptoms reduced in individuals with HIV/AIDS treated with highly active antiretroviral therapy: a longitudinal study. Aust NZ J Psychiatry 2000;34:1015-1021
5. Owe-Larsson B, Säll L, Salamon E, Allgulander C. HIV infection and psychiatric illness. Afr J Psychiatry 2009;12:115-128
6. Johnson MO, Stallworth T, Neilands TB. The drugs or the disease? Causal attributions of symptoms held by HIV-positive adults on HAART. AIDS Behav 2003;7:109-117
7. Arendt G, de Nocker D, von Giesen HJ, Nolting T. Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf 2007;6:147-154
8. Deeks SG. Antiretroviral agents: the next generation. AIDS Clin Care 1998;10:33-36, 39-40
9. Molina JM, Ferchal F, Rancinan C, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis 2000;182:599-602
10. Ward DJ, Curtin JM. Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. AIDS Patient Care STDS 2006;20:542-548
11. Perry S, Bangsberg DR, Charlesbois ED, et al. Depressive Symptoms Predict Mortality and HAART Adherence. Presented at 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, 2001; Chicago, IL. Abstract I-1721
12. Tate D, Paul RH, Flanigan TP, et al. The impact of apathy and depression on quality of life in patients infected with HIV. AIDS Patient Care STDS 2003;17:115-120
13. Journot V, Chene G, De Castro N, et al. and the ALIZE Study Group. Use of efavirenz is not associated with a higher risk of depressive disorders: a sub study of the randomized clinical trial ALIZE-ANRS 099. Clin Infect Dis 2006;42:1790-1799
14. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007;69:1789-1799
15. Rothenhäusler HB. Klinik, Diagnostik und Therapie HIV-induzierter neuropsychiatrischer Störungen. Wien Med Wochenschr 2006;156/23-24: 644-656
16. Boly L, Cafaro V, Dyner T. Depressive symptoms predict increased incidence of neuropsychiatric side effects in patients treated with efavirenz. J Acquir Immune Defic Syndr 2006;42:514-515
17. Gutierrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. CID 2005;41:1648-1653
18. Puzantian T. Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy 2002;22:930-933
19. Colebunders R, Hilbrands R, De Roo A, Pelgrom J. Neuropsychiatric reaction induced by abacavir. Am J Med 2002;113:616
20. Harry TC, Matthews M, Salvary I. Indinavir use: associated reversible hair loss and mood disturbance. Int J STD AIDS 2000;11:474-476
21. Hawkins T, Geist C, Young B, et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials 2005;6:187-196
22. Perkins D, Evans DL. HIV-related major depression: response to zidovudine treatment. Psychosomatics 1991;32:451-454
23. Wise MEJ. Neuropsychiatric complications of nevirapine treatment. BMJ 2002;324:879
24. von Giesen HJ, Köller H, de Nocker D, Haslinger BA, Arendt G. Long-term safety and efficacy of NNRTI witin the central nervous system. HIV Clin Trials 2003;4:382-390
25. von Einsiedel RW, Berger T, Weisbrod M, Unvverricht S, Hartmann M. HIV patients with psychiatric diseases: treatment strategies and pharmacological interaction. Nervenarzt 2001;72:204-215
26. Bickel M, Stephan C, Rottmann C, et al. Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis. Scand J Infect Dis 2005;37:520-522
27. Lang JP, Halleguen O, Picard A, Lang JM, Danion JM. Apropos of atypical melancholia with Sustiva (efavirenz) [in French]. Encepahale 2001;27:290-293
28. de la Tribonnière X, Dufresne MD, Alfandari S, et al. Tolerance, compliance and psychological consequences of post-exposure prophylaxis in health care workers. Int J STD AIDS 1998;9:591-594
29. Gelmon K, Montaner JSG, Fanning M, et al. Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial. AIDS 1989;3:555-561
30. Maxwell S, Schefter WA, Kessler HA, Busch K. Manic syndrome associated with zidovudine treatment. JAMA 1988;259:3406-3407
31. O'Dowd MA, McKegney F. Manic syndrome associated with zidovudine. JAMA 1988;260:3587
32. Schaerf FW, Miller R, Pearlson GD, Kaminsky MJ, Weaver D. Manic syndrome associated with zidovudine. JAMA 1988;259:3406
33. Sheehan NL, Brouillette MJ, Delisle MS, Allan J. Possible interaction between lopinavir/ritonavir and valproic acid exacerbates bipolar disorder. Ann Pharmacother 2006;40:147-150
34. Wright JM, Sachdev PS, Perkins RJ, Rodriguez P. Zidovudine-related mania. Med J Aust 1989;150:339-341
35. Staff author. New drugs: amprenavir and abacavir. Treatment Update. 1998;10:3-4
36. Foster R, Olajide D, Everall IP. Antiretroviral therapy-induced psychosis: case report and brief review of literature. HIV Med 2003;4:139-144
37. Foster R, Taylor C, Everall IP. More on abacavir-induced neuropsychiatric reactions. AIDS 2004;18:2449
38. Feldt T, Oette M, Kroidl A, et al. Atazanavir for treatment of HIV infection in clinical routine: efficacy, pharmacokinetics and safety. Eur J Med Res 2005;10:7-10
39. Blanch J, Martinez E, Rousaud A, et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr 2001;27:336-343
40. Dubé B, Benton T, Cruess DG, Evans DL. Neuropsychiatric manifestations of HIV infection and AIDS. J Psychiatry Neurosi 2005;30:237-246
41. Carrieri MP, Leport C, Protopopescu C, et al. Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. J Acquir Immune Defic Syndr 2006;41:477-485
42. Lafeuillade A. Factors affecting adherence and convenience in antiretroviral therapy. Int J STD AIDS 2001;12:18-24
43. Sambamoorthi U, Walkup J, Olfson M, Crystal S. Antidepressant treatment and health services utilization among HIV-infected medicaid patients diagnosed with depression. J Gen Intern Med 2000;15:311-320
44. ÓMahony SM, Myint AM, Steinbusch H, Leonard BE. Efavirenz induces stress response and changes in the immune response in rats. Neuroimmunomodulation 2005;12:293-298
45. Collazos J, Ibarra S, Loureiro M. Cortisol serum levels and their relationship to certain antiretroviral drugs. Scand J Infect Dis 2004;36:480-482
46. Zapanti E, Terzidis K, Chrousos G. Dysfunction of the hypothalamic- pituitary-adrenal axis in HIV infection and disease. Hormones 2008;7:205-216
47. Leonard BE, Myint A. The psychoneuroimmunology of depression. Hum Psychopharmacol 2009;24:165-175
48. Kumar M, Kumar AM, Waldrop D, Antoni MH, Eisdorfer C. HIV-1 infection and its impact on the HPA axis, cytokines, and cognition. Stress 2003;6:167-172
49. Thompson A, Silverman B, Dzeng L, Treisman G. Psychotropic medications and HIV. Clin Infect Dis 2006;42:1305-1310
50. Ma Q, Okusanya OO, Smith PF, et al. Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opin Drug Metab Toxicol 2005;1:473-1485
51. Miller RF, Dave SS, Tang JW, Shaw PJ, Jäger HR, Wilkins EGL. Progressive neuropsychiatric problems following institution of highly active antiretroviral therapy. Sex Transm Infect 2005;81:351-357
52. Moreno A, Labelle C, Samet JH. Recurrence of post-traumatic stress disorder symptoms after initiation of antiretrovirals including efavirenz: a report of two cases. HIV Med 2003;4:302-304
53. Fumaz CR, Tuldra A, Ferrer MJ, et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efevirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr 2002;29:244-253
54. Hartmann M, Rump A, Brust J, et al. Evaluation of an efavirenz-containing regimen: an open-label, multicenter study. HIV Clin Trials 2001;2:421-428
55. Knechten H, Stürner KH, Höhn C, Braun P. Switch to efavirenz in a protease inhibitor-containing regimen. HIV Clin Trials 2001;2:200-204
56. Lochet P, Peyriere H, Lotte A, Mauboussin JM, Delmas B, Reynes J. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med 2003;4:62-66
57. Poupard M, Gueye NFN, Thiam D, et al. Quality of life and depression among HIV-infected patients receiving efavirenz- or protease inhibitor-based therapy in Senegal. HIV Med 2007;8:92-95
58. Rhis TA, Begley K, Smith DE, et al. Efavirenz and chronic neuropsychiatric symptoms: a cross-sectionsl case control study. HIV Med 2006;7:544-548
59. van Leth F, Phanuphak P, Baraldi E, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004;363:1253-1263